首页 > 最新文献

Liver International最新文献

英文 中文
Herbal-Induced Liver Injury Identification and Prevention. 中草药诱发肝损伤的识别与预防。
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-28 DOI: 10.1111/liv.16154
Huang Nan, Xiang Liu, Zheng Liu
{"title":"Herbal-Induced Liver Injury Identification and Prevention.","authors":"Huang Nan, Xiang Liu, Zheng Liu","doi":"10.1111/liv.16154","DOIUrl":"https://doi.org/10.1111/liv.16154","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply: Herbal-Induced Liver Injury Identification and Prevention. 回复:中草药诱发肝损伤的识别与预防。
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-28 DOI: 10.1111/liv.16160
Dina Halegoua-DeMarzio, Victor Navarro
{"title":"Reply: Herbal-Induced Liver Injury Identification and Prevention.","authors":"Dina Halegoua-DeMarzio, Victor Navarro","doi":"10.1111/liv.16160","DOIUrl":"https://doi.org/10.1111/liv.16160","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dietary Habits of Individuals With Primary Sclerosing Cholangitis-Poor Fat-Soluble Vitamin Intake and Dietary Quality. 原发性硬化性胆管炎患者的饮食习惯--脂溶性维生素摄入量和膳食质量较差。
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-27 DOI: 10.1111/liv.16182
Catarina Lindqvist, Michael Ingre, Stergios Kechagias, Emma Nilsson, Antonio Molinaro, Fredrik Rorsman, Annika Bergquist

Background and aims: Individuals with primary sclerosing cholangitis (PSC) have expressed a need for more dietary information. The aim of this study was to evaluate the dietary intake of individuals with PSC and compare it with Nordic nutrition recommendations 2023 (NNR2023).

Methods: A cross-sectional assessment of dietary intake was performed using a food-frequency questionnaire among 120 individuals with PSC from five regions across Sweden. Macro- and micronutrient intake was compared to NNR2023. Dietary quality was evaluated using an index developed by the National Food Agency in Sweden.

Results: The median age was 47 years (IQR 18), and median body mass index (BMI) was 25.2 kg/m2 (IQR 5.9). Eight percent had a BMI < 20, and 13% had a BMI > 30. The average fibre intake was 18 g (IQR 18). Median energy distribution included 36% from fat (15% saturated, 4.6% polyunsaturated), 17% from protein and 43% from carbohydrates, highlighting an imbalanced diet with low carbohydrate, fibre and polyunsaturated fat intake and high saturated fat consumption. More than half reported suboptimal intake of zinc, selenium and vitamins C, D and K and > 30% suboptimal intake of vitamins A, B6, E, niacin, folate, potassium, magnesium and iron. Forty percent had poor dietary quality. Longer PSC duration and previous colectomy were associated with a lower dietary quality.

Conclusions: Many individuals with PSC do not reach the recommended levels of various micronutrients, especially fat-soluble vitamins and report a poor dietary quality. The results highlight the need for a comprehensive approach to nutritional management in this population.

Trial registration: ClinicalTrials.gov identifier: NCT04133792.

背景和目的:原发性硬化性胆管炎(PSC)患者表示需要更多的饮食信息。本研究旨在评估原发性硬化性胆管炎患者的饮食摄入量,并将其与北欧营养建议 2023(NNR2023)进行比较:方法:采用食物频率问卷对瑞典五个地区的120名PSC患者的膳食摄入量进行了横断面评估。宏观营养素和微量营养素摄入量与 NNR2023 进行了比较。膳食质量采用瑞典国家食品局制定的指数进行评估:中位年龄为 47 岁(IQR 18),中位体重指数(BMI)为 25.2 kg/m2(IQR 5.9)。8%的人体重指数为 30。平均纤维摄入量为 18 克(IQR 18)。能量分布中位数包括 36% 的脂肪(15% 饱和脂肪,4.6% 多不饱和脂肪)、17% 蛋白质和 43% 碳水化合物,这表明饮食不均衡,碳水化合物、纤维和多不饱和脂肪摄入量低,而饱和脂肪摄入量高。半数以上的人报告锌、硒和维生素 C、D 和 K 的摄入量不足,超过 30% 的人报告维生素 A、B6、E、烟酸、叶酸、钾、镁和铁的摄入量不足。40%的人饮食质量较差。PSC病程较长和曾接受过结肠切除术与饮食质量较低有关:结论:许多帕金森氏综合症患者的各种微量营养素,尤其是脂溶性维生素的摄入量达不到推荐水平,而且膳食质量较差。结论:许多帕金森病患者的各种微量营养素达不到推荐水平,尤其是脂溶性维生素,而且他们的膳食质量很差。研究结果突出表明,需要对这一人群进行全面的营养管理:试验注册:ClinicalTrials.gov identifier:NCT04133792.
{"title":"Dietary Habits of Individuals With Primary Sclerosing Cholangitis-Poor Fat-Soluble Vitamin Intake and Dietary Quality.","authors":"Catarina Lindqvist, Michael Ingre, Stergios Kechagias, Emma Nilsson, Antonio Molinaro, Fredrik Rorsman, Annika Bergquist","doi":"10.1111/liv.16182","DOIUrl":"https://doi.org/10.1111/liv.16182","url":null,"abstract":"<p><strong>Background and aims: </strong>Individuals with primary sclerosing cholangitis (PSC) have expressed a need for more dietary information. The aim of this study was to evaluate the dietary intake of individuals with PSC and compare it with Nordic nutrition recommendations 2023 (NNR2023).</p><p><strong>Methods: </strong>A cross-sectional assessment of dietary intake was performed using a food-frequency questionnaire among 120 individuals with PSC from five regions across Sweden. Macro- and micronutrient intake was compared to NNR2023. Dietary quality was evaluated using an index developed by the National Food Agency in Sweden.</p><p><strong>Results: </strong>The median age was 47 years (IQR 18), and median body mass index (BMI) was 25.2 kg/m<sup>2</sup> (IQR 5.9). Eight percent had a BMI < 20, and 13% had a BMI > 30. The average fibre intake was 18 g (IQR 18). Median energy distribution included 36% from fat (15% saturated, 4.6% polyunsaturated), 17% from protein and 43% from carbohydrates, highlighting an imbalanced diet with low carbohydrate, fibre and polyunsaturated fat intake and high saturated fat consumption. More than half reported suboptimal intake of zinc, selenium and vitamins C, D and K and > 30% suboptimal intake of vitamins A, B6, E, niacin, folate, potassium, magnesium and iron. Forty percent had poor dietary quality. Longer PSC duration and previous colectomy were associated with a lower dietary quality.</p><p><strong>Conclusions: </strong>Many individuals with PSC do not reach the recommended levels of various micronutrients, especially fat-soluble vitamins and report a poor dietary quality. The results highlight the need for a comprehensive approach to nutritional management in this population.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT04133792.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Endoscopic Ultrasound in Assessing Portal Hypertension: A State-of-the-Art Literature Review and Evolving Perspectives. 内窥镜超声在评估门脉高压中的作用:最新文献综述与不断发展的观点。
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-27 DOI: 10.1111/liv.16176
Fabrizio Termite, Federica Borrelli de Andreis, Antonio Liguori, Antonio Gasbarrini, Fabia Attili, Cristiano Spada, Luca Miele

Background: Portal hypertension (PH) is a critical complication in patients with hepatic diseases. Its accurate evaluation is essential for early diagnosis, risk stratification, and management. Endoscopic ultrasound (EUS) has emerged as a promising diagnostic tool, offering high-resolution imaging of the portal venous system, hepatic vasculature, and surrounding structures.

Aims: This review aims at providing an overview of the evolving role of EUS in PH evaluation in patients with liver disease.

Materials and methods: A systematic search was conducted in PubMed and Google Scholar until 31 May 2024. Relevant studies were identified using keywords related to EUS and PH. Additional references were included based on expert knowledge and citation analysis. Only full-length papers and abstracts in English were considered.

Results: EUS demonstrates significant utility in PH assessment, offering high-resolution imaging and advanced tools like contrast enhancement (CE) and shear-wave elastography (SWE) for evaluating liver stiffness and correlating it with PH severity. EUS-guided portal pressure gradient (PPG) measurement provides a less invasive method for evaluating PH, potentially offering a safer alternative to conventional techniques.

Discussion: EUS offers unique advantages in PH assessment, enabling comprehensive evaluation in a single session. Despite its potential, limitations such as invasiveness, sedation-related variability, and restricted availability persist. Emerging techniques require further validation in larger cohorts and standardised training.

Conclusion: EUS is a valuable diagnostic tool for PH evaluation, with the potential to improve outcomes through earlier diagnosis and better stratification. Addressing its limitations through further research and standardised protocols is critical to optimize its clinical utility.

Trial registration: NCT04115046, NCT05728697, NCT05097963 and NCT03155282.

背景:门静脉高压症(PH)是肝病患者的一个重要并发症。对其进行准确评估对于早期诊断、风险分层和管理至关重要。目的:本综述旨在概述 EUS 在肝病患者门静脉高压评估中不断发展的作用:截至 2024 年 5 月 31 日,在 PubMed 和 Google Scholar 上进行了系统检索。使用与 EUS 和 PH 相关的关键词确定了相关研究。根据专家知识和引文分析纳入其他参考文献。仅考虑英文全文和摘要:EUS 在 PH 评估中具有重要作用,它提供了高分辨率成像以及造影剂增强(CE)和剪切波弹性成像(SWE)等先进工具,用于评估肝脏硬度并将其与 PH 的严重程度相关联。EUS 引导下的门静脉压力梯度(PPG)测量为 PH 评估提供了一种创伤较小的方法,有可能成为传统技术更安全的替代方法:讨论:EUS 在 PH 评估方面具有独特的优势,可在一次治疗中进行全面评估。尽管其潜力巨大,但仍存在一些局限性,如侵入性、镇静相关变异性和可用性受限。新出现的技术需要在更大的群体和标准化培训中得到进一步验证:EUS 是 PH 评估的重要诊断工具,有可能通过更早的诊断和更好的分层来改善预后。通过进一步研究和标准化方案解决其局限性对于优化其临床实用性至关重要:试验注册:NCT04115046、NCT05728697、NCT05097963和NCT03155282。
{"title":"The Role of Endoscopic Ultrasound in Assessing Portal Hypertension: A State-of-the-Art Literature Review and Evolving Perspectives.","authors":"Fabrizio Termite, Federica Borrelli de Andreis, Antonio Liguori, Antonio Gasbarrini, Fabia Attili, Cristiano Spada, Luca Miele","doi":"10.1111/liv.16176","DOIUrl":"https://doi.org/10.1111/liv.16176","url":null,"abstract":"<p><strong>Background: </strong>Portal hypertension (PH) is a critical complication in patients with hepatic diseases. Its accurate evaluation is essential for early diagnosis, risk stratification, and management. Endoscopic ultrasound (EUS) has emerged as a promising diagnostic tool, offering high-resolution imaging of the portal venous system, hepatic vasculature, and surrounding structures.</p><p><strong>Aims: </strong>This review aims at providing an overview of the evolving role of EUS in PH evaluation in patients with liver disease.</p><p><strong>Materials and methods: </strong>A systematic search was conducted in PubMed and Google Scholar until 31 May 2024. Relevant studies were identified using keywords related to EUS and PH. Additional references were included based on expert knowledge and citation analysis. Only full-length papers and abstracts in English were considered.</p><p><strong>Results: </strong>EUS demonstrates significant utility in PH assessment, offering high-resolution imaging and advanced tools like contrast enhancement (CE) and shear-wave elastography (SWE) for evaluating liver stiffness and correlating it with PH severity. EUS-guided portal pressure gradient (PPG) measurement provides a less invasive method for evaluating PH, potentially offering a safer alternative to conventional techniques.</p><p><strong>Discussion: </strong>EUS offers unique advantages in PH assessment, enabling comprehensive evaluation in a single session. Despite its potential, limitations such as invasiveness, sedation-related variability, and restricted availability persist. Emerging techniques require further validation in larger cohorts and standardised training.</p><p><strong>Conclusion: </strong>EUS is a valuable diagnostic tool for PH evaluation, with the potential to improve outcomes through earlier diagnosis and better stratification. Addressing its limitations through further research and standardised protocols is critical to optimize its clinical utility.</p><p><strong>Trial registration: </strong>NCT04115046, NCT05728697, NCT05097963 and NCT03155282.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microvesicle Tissue Factor Procoagulant Activity Is Elevated and Correlated With Disease Severity in Patients With Cirrhosis. 肝硬化患者微囊组织因子促凝血活性升高并与疾病严重程度相关。
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-27 DOI: 10.1111/liv.16192
Adonis A Protopapas, Anna Takardaki, Nefeli Protopapa, Ioanna Papagiouvanni, Andreas N Protopapas, Lemonia Skoura, Christos Savopoulos, Ioannis Goulis

Background and aims: Tissue factor-expressing microvesicles (MV-TF) have been found to correlate with thrombotic complications in various diseases. Simultaneously, there is expanding research regarding the effect of the coagulation cascade on liver fibrosis progression. The aim of our manuscript was to evaluate MV-TF activity in patients with cirrhosis and its correlation with disease severity.

Methods: We prospectively enrolled 82 patients [11 with cirrhosis and hepatocellular cancer (Group 1), 50 with cirrhosis (Group 2) and 21 controls (Group 3)]. Extensive workup for disease staging and exclusion criteria was undertaken. Exclusion criteria included thrombophilia, history of thrombosis, recent hospitalisation, ongoing infection, alcohol dependence, cancer, haematological diseases and use of anticoagulant, antiplatelet or contraceptive drugs. Plasma tissue factor antigen concentration and MV-TF activity were assessed.

Results: MV-TF showed median values of 4.03 [1.57], 3.17 [1.59] and 2.26 [1.23] pg/mL in Groups 1, 2 and 3, respectively. There was a statistically significant difference between Groups 1 and 3 (p < 0.001) and Groups 2 and 3 (p = 0.003), while Group 1 had higher values than Group 2 without statistical significance (p = 0.088). In Group 2, the patients' Child-Pugh (CP) stage was A in 56%, B in 26% and C in 18% of cases. MV-TF activity significantly correlated with decompensated cirrhosis (p = 0.005) and higher CP stage (p = 0.011). Finally, MV-TF activity significantly correlated with 12-month mortality (p = 0.021).

Conclusions: MV-TF activity is elevated in patients with cirrhosis, showing a significant correlation with disease severity. MV-TF may play a role in the procoagulant imbalance of liver cirrhosis and their contribution in disease progression should be studied further.

背景和目的:研究发现,组织因子表达微囊(MV-TF)与多种疾病的血栓并发症相关。与此同时,有关凝血级联对肝纤维化进展的影响的研究也在不断扩大。我们的研究旨在评估肝硬化患者的 MV-TF 活性及其与疾病严重程度的相关性:我们前瞻性地招募了 82 名患者[11 名肝硬化合并肝细胞癌患者(第 1 组)、50 名肝硬化患者(第 2 组)和 21 名对照组患者(第 3 组)]。我们进行了广泛的疾病分期和排除标准检查。排除标准包括血栓性疾病、血栓形成史、近期住院、持续感染、酒精依赖、癌症、血液病以及使用抗凝剂、抗血小板药物或避孕药物。对血浆组织因子抗原浓度和 MV-TF 活性进行了评估:第一组、第二组和第三组的 MV-TF 中位值分别为 4.03 [1.57]、3.17 [1.59] 和 2.26 [1.23] pg/mL。第 1 组和第 3 组之间的差异具有统计学意义(p 结论:第 1 组和第 3 组之间的差异具有统计学意义(p):肝硬化患者的 MV-TF 活性升高,与疾病严重程度有显著相关性。MV-TF 可能在肝硬化的促凝失衡中发挥作用,应进一步研究其在疾病进展中的作用。
{"title":"Microvesicle Tissue Factor Procoagulant Activity Is Elevated and Correlated With Disease Severity in Patients With Cirrhosis.","authors":"Adonis A Protopapas, Anna Takardaki, Nefeli Protopapa, Ioanna Papagiouvanni, Andreas N Protopapas, Lemonia Skoura, Christos Savopoulos, Ioannis Goulis","doi":"10.1111/liv.16192","DOIUrl":"https://doi.org/10.1111/liv.16192","url":null,"abstract":"<p><strong>Background and aims: </strong>Tissue factor-expressing microvesicles (MV-TF) have been found to correlate with thrombotic complications in various diseases. Simultaneously, there is expanding research regarding the effect of the coagulation cascade on liver fibrosis progression. The aim of our manuscript was to evaluate MV-TF activity in patients with cirrhosis and its correlation with disease severity.</p><p><strong>Methods: </strong>We prospectively enrolled 82 patients [11 with cirrhosis and hepatocellular cancer (Group 1), 50 with cirrhosis (Group 2) and 21 controls (Group 3)]. Extensive workup for disease staging and exclusion criteria was undertaken. Exclusion criteria included thrombophilia, history of thrombosis, recent hospitalisation, ongoing infection, alcohol dependence, cancer, haematological diseases and use of anticoagulant, antiplatelet or contraceptive drugs. Plasma tissue factor antigen concentration and MV-TF activity were assessed.</p><p><strong>Results: </strong>MV-TF showed median values of 4.03 [1.57], 3.17 [1.59] and 2.26 [1.23] pg/mL in Groups 1, 2 and 3, respectively. There was a statistically significant difference between Groups 1 and 3 (p < 0.001) and Groups 2 and 3 (p = 0.003), while Group 1 had higher values than Group 2 without statistical significance (p = 0.088). In Group 2, the patients' Child-Pugh (CP) stage was A in 56%, B in 26% and C in 18% of cases. MV-TF activity significantly correlated with decompensated cirrhosis (p = 0.005) and higher CP stage (p = 0.011). Finally, MV-TF activity significantly correlated with 12-month mortality (p = 0.021).</p><p><strong>Conclusions: </strong>MV-TF activity is elevated in patients with cirrhosis, showing a significant correlation with disease severity. MV-TF may play a role in the procoagulant imbalance of liver cirrhosis and their contribution in disease progression should be studied further.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment: Prevalence, Trends and Distribution of HCV Among the General Population in Sub-Saharan Africa: An SLR-MA. 评论:评论:撒哈拉以南非洲普通人群中丙型肝炎病毒的流行率、趋势和分布:SLR-MA。
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-26 DOI: 10.1111/liv.16122
Aashima Walia, Muhammed Shabil, Sanjit Sah
{"title":"Comment: Prevalence, Trends and Distribution of HCV Among the General Population in Sub-Saharan Africa: An SLR-MA.","authors":"Aashima Walia, Muhammed Shabil, Sanjit Sah","doi":"10.1111/liv.16122","DOIUrl":"https://doi.org/10.1111/liv.16122","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Response to the Letter to the Editor by Walia et al. RE: Kassa et al. 2024 'Prevalence, Trends, and Distribution of Hepatitis C Virus Among the General Population in Sub-Saharan Africa: A Systematic Review and Meta-Analysis'. 回应 Walia 等人写给编辑的信,回复:Kassa 等人,2024 年 "撒哈拉以南非洲普通人群中丙型肝炎病毒的流行、趋势和分布:系统回顾与元分析》。
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-26 DOI: 10.1111/liv.16170
Getahun Molla Kassa, Josephine G Walker, Aaron G Lim, Clare E French
{"title":"In Response to the Letter to the Editor by Walia et al. RE: Kassa et al. 2024 'Prevalence, Trends, and Distribution of Hepatitis C Virus Among the General Population in Sub-Saharan Africa: A Systematic Review and Meta-Analysis'.","authors":"Getahun Molla Kassa, Josephine G Walker, Aaron G Lim, Clare E French","doi":"10.1111/liv.16170","DOIUrl":"https://doi.org/10.1111/liv.16170","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Air Pollution in Development of Hepatocellular Carcinoma Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues. 空气污染在接受核苷酸/核苷类似物治疗的慢性乙型肝炎患者肝细胞癌发病中的作用
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-26 DOI: 10.1111/liv.16149
Tyng-Yuan Jang, Yu-Ting Zeng, Po-Cheng Liang, Chih-Da Wu, Yu-Ju Wei, Pei-Chien Tsai, Po-Yao Hsu, Ming-Yen Hsieh, Yi-Hung Lin, Meng-Hsuan Hsieh, Chih-Wen Wang, Jeng-Fu Yang, Ming-Lun Yeh, Chung-Feng Huang, Wan-Long Chuang, Jee-Fu Huang, Ya-Yun Cheng, Chia-Yen Dai, Pau-Chung Chen, Ming-Lung Yu

Background and aims: To investigate the association between air pollution and hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with nucleotide/nucleoside analogues.

Methods: We enrolled 1298 CHB patients treated with nucleotide/nucleoside analogues and analysed the incidence and risk factors for HCC. Daily estimates of air pollutants were estimated since the previous year from the enrolment date.

Results: The annual incidence of HCC was 2.1/100 person-years after a follow-up period of over 4840.5 person-years. Factors with the strongest association with HCC development were liver cirrhosis (hazard ratio [HR]/95% confidence interval [CI]: 3.00/1.55-5.81; p = 0.001), male sex (2.98/1.51-5.90; p = 0.02), body mass index (1.11/1.04-1.18; p = 0.002) and age (1.06/1.04-1.09; p < 0.001). Among patients with cirrhosis, the factors associated with HCC development were male sex (HR/95% CI: 2.10/1.00-4.25; p = 0.04) and NO2 (per one-unit increment, parts per billion; 1.07/1.01-1.13; p = 0.01). Moreover, patients with the highest quartile of annual NO2 exposure had more than a three-fold risk of HCC than those with the lowest quartile of annual exposure (HR/95% CI: 3.26/1.34-7.93; p = 0.01). Among patients without cirrhosis, the strongest factors associated with HCC development were male sex (HR/95% CI: 5.86/1.79-19.23; p = 0.004), age (1.12/1.07-1.17; p < 0.001) and platelet count (0.99/0.98-1.00; p = 0.04).

Conclusions: Air pollution influences HCC development in CHB patients who receive nucleotide/nucleoside analogue therapy. Long-term NO2 exposure might accelerate HCC development in CHB patients with cirrhosis receiving nucleotide/nucleoside analogue treatment.

背景和目的研究空气污染与接受核苷酸/核苷类似物治疗的慢性乙型肝炎(CHB)患者肝细胞癌(HCC)之间的关系:我们招募了1298名接受核苷酸/核苷类似物治疗的CHB患者,分析了HCC的发病率和风险因素。结果:HCC的年发病率为2.5%:结果:在超过 4840.5 年的随访期后,HCC 的年发病率为 2.1/100人年。肝硬化(危险比 [HR]/95% 置信区间 [CI]:3.00/1.55-5.81;P = 0.001)、男性(2.98/1.51-5.90;P = 0.02)、体重指数(1.11/1.04-1.18;P = 0.002)和年龄(1.06/1.04-1.09;P 2(每一单位增量,十亿分之一;1.07/1.01-1.13;P = 0.01)。此外,年二氧化氮暴露量最高四分位数的患者患 HCC 的风险是年暴露量最低四分位数患者的三倍多(HR/95% CI:3.26/1.34-7.93;P = 0.01)。在没有肝硬化的患者中,与 HCC 发展相关性最强的因素是男性(HR/95% CI:5.86/1.79-19.23;P = 0.004)、年龄(1.12/1.07-1.17;P 结论:空气污染影响慢性肺癌患者的 HCC 发展:空气污染会影响接受核苷酸/核苷类似物治疗的慢性阻塞性肺疾病患者的HCC发展。长期暴露于二氧化氮可能会加速接受核苷酸/核苷类似物治疗的肝硬化 CHB 患者的 HCC 发展。
{"title":"Role of Air Pollution in Development of Hepatocellular Carcinoma Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues.","authors":"Tyng-Yuan Jang, Yu-Ting Zeng, Po-Cheng Liang, Chih-Da Wu, Yu-Ju Wei, Pei-Chien Tsai, Po-Yao Hsu, Ming-Yen Hsieh, Yi-Hung Lin, Meng-Hsuan Hsieh, Chih-Wen Wang, Jeng-Fu Yang, Ming-Lun Yeh, Chung-Feng Huang, Wan-Long Chuang, Jee-Fu Huang, Ya-Yun Cheng, Chia-Yen Dai, Pau-Chung Chen, Ming-Lung Yu","doi":"10.1111/liv.16149","DOIUrl":"https://doi.org/10.1111/liv.16149","url":null,"abstract":"<p><strong>Background and aims: </strong>To investigate the association between air pollution and hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with nucleotide/nucleoside analogues.</p><p><strong>Methods: </strong>We enrolled 1298 CHB patients treated with nucleotide/nucleoside analogues and analysed the incidence and risk factors for HCC. Daily estimates of air pollutants were estimated since the previous year from the enrolment date.</p><p><strong>Results: </strong>The annual incidence of HCC was 2.1/100 person-years after a follow-up period of over 4840.5 person-years. Factors with the strongest association with HCC development were liver cirrhosis (hazard ratio [HR]/95% confidence interval [CI]: 3.00/1.55-5.81; p = 0.001), male sex (2.98/1.51-5.90; p = 0.02), body mass index (1.11/1.04-1.18; p = 0.002) and age (1.06/1.04-1.09; p < 0.001). Among patients with cirrhosis, the factors associated with HCC development were male sex (HR/95% CI: 2.10/1.00-4.25; p = 0.04) and NO<sub>2</sub> (per one-unit increment, parts per billion; 1.07/1.01-1.13; p = 0.01). Moreover, patients with the highest quartile of annual NO<sub>2</sub> exposure had more than a three-fold risk of HCC than those with the lowest quartile of annual exposure (HR/95% CI: 3.26/1.34-7.93; p = 0.01). Among patients without cirrhosis, the strongest factors associated with HCC development were male sex (HR/95% CI: 5.86/1.79-19.23; p = 0.004), age (1.12/1.07-1.17; p < 0.001) and platelet count (0.99/0.98-1.00; p = 0.04).</p><p><strong>Conclusions: </strong>Air pollution influences HCC development in CHB patients who receive nucleotide/nucleoside analogue therapy. Long-term NO<sub>2</sub> exposure might accelerate HCC development in CHB patients with cirrhosis receiving nucleotide/nucleoside analogue treatment.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to 'Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR-MASH Score'. 对 "用于识别代谢功能障碍相关性脂肪性肝炎的图像生物标志物的开发与验证:MR-MASH 评分"。
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-26 DOI: 10.1111/liv.16190

Marti-Aguado D, Arnouk J, Liang JX, Lara-Romero C, Behari J, Furlan A, Jimenez-Pastor A, Ten-Esteve A, Alfaro-Cervello C, Bauza M, Gallen-Peris A, Gimeno-Torres M, Merino-Murgui V, Perez-Girbes A, Benlloch S, Pérez-Rojas J, Puglia V, Ferrández-Izquierdo A, Aguilera V, Giesteira B, França M, Monton C, Escudero-García D, Alberich-Bayarri Á, Serra MA, Bataller R, Romero-Gomez M, Marti-Bonmati L. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score. Liver Int. 2024 Jan; 44(1):202-213. doi: 10.1111/liv.15766. Epub 2023 Oct 30. PMID: 37904633. It has come to our attention that there was a mistake in the published version of our manuscript. The mistake in page 5 has resulted in an error in the units of the variable height from the MR-MASH score. The height should be expressed in meters and not in centimetres. The correct MR-MASH formula is as follows: [Formula: see text] This has been corrected in the online version. We apologise for this error.

Marti-Aguado D、Arnouk J、Liang JX、Lara-Romero C、Behari J、Furlan A、Jimenez-Pastor A、Ten-Esteve A、Alfaro-Cervello C、Bauza M、Gallen-Peris A、Gimeno-Torres M、Merino-Murgui V、Perez-Girbes A、Benlloch S, Pérez-Rojas J, Puglia V, Ferrández-Izquierdo A, Aguilera V, Giesteira B, França M, Monton C, Escudero-García D, Alberich-Bayarri Á, Serra MA, Bataller R, Romero-Gomez M, Marti-Bonmati L.开发和验证图像生物标志物,以识别与代谢功能障碍相关的脂肪性肝炎:MR-MASH评分。Liver Int. 2024 Jan; 44(1):202-213. Doi: 10.1111/liv.15766.Epub 2023 Oct 30.PMID:37904633。我们注意到,我们的手稿出版版本中有一处错误。第 5 页中的错误导致了 MR-MASH 评分中身高变量单位的错误。身高应该用米而不是厘米来表示。正确的 MR-MASH 公式如下:[公式:见正文] 该错误已在网络版中更正。我们对此错误深表歉意。
{"title":"Correction to 'Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR-MASH Score'.","authors":"","doi":"10.1111/liv.16190","DOIUrl":"https://doi.org/10.1111/liv.16190","url":null,"abstract":"<p><p>Marti-Aguado D, Arnouk J, Liang JX, Lara-Romero C, Behari J, Furlan A, Jimenez-Pastor A, Ten-Esteve A, Alfaro-Cervello C, Bauza M, Gallen-Peris A, Gimeno-Torres M, Merino-Murgui V, Perez-Girbes A, Benlloch S, Pérez-Rojas J, Puglia V, Ferrández-Izquierdo A, Aguilera V, Giesteira B, França M, Monton C, Escudero-García D, Alberich-Bayarri Á, Serra MA, Bataller R, Romero-Gomez M, Marti-Bonmati L. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score. Liver Int. 2024 Jan; 44(1):202-213. doi: 10.1111/liv.15766. Epub 2023 Oct 30. PMID: 37904633. It has come to our attention that there was a mistake in the published version of our manuscript. The mistake in page 5 has resulted in an error in the units of the variable height from the MR-MASH score. The height should be expressed in meters and not in centimetres. The correct MR-MASH formula is as follows: [Formula: see text] This has been corrected in the online version. We apologise for this error.</p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Additional Cover 附加封面
IF 6 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-25 DOI: 10.1111/liv.16193
Eric Kalo, Lukas Sturm, Michael Schultheiss, Oliver Moore, Rajiv Kurup, Chiara Gahm, Scott Read, Marlene Reincke, Jan Patrick Huber, Lukas Müller, Roman Kloeckner, Jacob George, Robert Thimme, Dominik Bettinger, Golo Ahlenstiel

Cover Image: The cover image is based on the Article The Freiburg Index of Post-TIPS Survival accurately predicts mortality in patients with acute decompensation of cirrhosis by Eric Kalo et al., https://doi.org/10.1111/liv.16098

封面图片:封面图片来自 Eric Kalo 等人撰写的文章《TIPS 后弗莱堡生存指数可准确预测肝硬化急性失代偿期患者的死亡率》,https://doi.org/10.1111/liv.16098。
{"title":"Additional Cover","authors":"Eric Kalo,&nbsp;Lukas Sturm,&nbsp;Michael Schultheiss,&nbsp;Oliver Moore,&nbsp;Rajiv Kurup,&nbsp;Chiara Gahm,&nbsp;Scott Read,&nbsp;Marlene Reincke,&nbsp;Jan Patrick Huber,&nbsp;Lukas Müller,&nbsp;Roman Kloeckner,&nbsp;Jacob George,&nbsp;Robert Thimme,&nbsp;Dominik Bettinger,&nbsp;Golo Ahlenstiel","doi":"10.1111/liv.16193","DOIUrl":"https://doi.org/10.1111/liv.16193","url":null,"abstract":"<p>Cover Image: The cover image is based on the Article <i>The Freiburg Index of Post-TIPS Survival accurately predicts mortality in patients with acute decompensation of cirrhosis</i> by Eric Kalo et al., https://doi.org/10.1111/liv.16098\u0000 \u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </p>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"44 12","pages":"ii"},"PeriodicalIF":6.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.16193","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142708386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Liver International
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1